FR23C1002I2 - 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse - Google Patents

2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse

Info

Publication number
FR23C1002I2
FR23C1002I2 FR23C1002C FR23C1002C FR23C1002I2 FR 23C1002 I2 FR23C1002 I2 FR 23C1002I2 FR 23C1002 C FR23C1002 C FR 23C1002C FR 23C1002 C FR23C1002 C FR 23C1002C FR 23C1002 I2 FR23C1002 I2 FR 23C1002I2
Authority
FR
France
Prior art keywords
migraine
benzamide
piperidin
trifluoro
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1002C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colucid Pharmaceuticals Inc
Original Assignee
Colucid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42826711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1002(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc
Publication of FR23C1002I1 publication Critical patent/FR23C1002I1/fr
Application granted granted Critical
Publication of FR23C1002I2 publication Critical patent/FR23C1002I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR23C1002C 2009-04-02 2023-01-11 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse Active FR23C1002I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16609709P 2009-04-02 2009-04-02
PCT/US2010/029810 WO2010115125A2 (en) 2009-04-02 2010-04-02 Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide

Publications (2)

Publication Number Publication Date
FR23C1002I1 FR23C1002I1 (fr) 2023-03-10
FR23C1002I2 true FR23C1002I2 (fr) 2023-11-24

Family

ID=42826711

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1002C Active FR23C1002I2 (fr) 2009-04-02 2023-01-11 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse

Country Status (26)

Country Link
US (3) US20100256187A1 (enExample)
EP (1) EP2413933B2 (enExample)
JP (9) JP5727457B2 (enExample)
KR (1) KR101697801B1 (enExample)
CN (2) CN102753171A (enExample)
AU (1) AU2010232497B2 (enExample)
CA (1) CA2757019C (enExample)
CY (2) CY1119785T1 (enExample)
DK (1) DK2413933T4 (enExample)
ES (1) ES2655881T5 (enExample)
FI (1) FIC20230001I1 (enExample)
FR (1) FR23C1002I2 (enExample)
HK (1) HK1243923A1 (enExample)
HR (1) HRP20171742T4 (enExample)
HU (2) HUE037261T2 (enExample)
IL (1) IL215483A (enExample)
LT (2) LT2413933T (enExample)
LU (1) LUC00295I2 (enExample)
MX (1) MX2011010359A (enExample)
NL (1) NL301214I2 (enExample)
NO (2) NO2413933T3 (enExample)
NZ (1) NZ596161A (enExample)
PL (1) PL2413933T5 (enExample)
PT (1) PT2413933T (enExample)
SI (1) SI2413933T2 (enExample)
WO (1) WO2010115125A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
KR101683042B1 (ko) 2008-04-04 2016-12-06 포사이트 비젼4, 인크. 통증 관리 및 시력을 위한 치료 장치
JP5727457B2 (ja) * 2009-04-02 2015-06-03 コルーシッド ファーマシューティカルズ， インコーポレイテッド ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
JP6310072B2 (ja) 2013-06-26 2018-04-11 ネクシスビジョン， インコーポレイテッド 屈折矯正のためのコンタクトレンズ
UA124433C2 (uk) 2016-12-06 2021-09-15 Колюсід Фармасьютікалз, Інк. Піридиноїлпіперидин, його застосування для лікування мігрені та фармацевтична композиція на його основі
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
WO2022086756A1 (en) 2020-10-19 2022-04-28 Journey1, Inc. Astigmatism correcting contact lenses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JPH03255426A (ja) 1990-03-06 1991-11-14 Toshiba Corp 有機非線形光学材料
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
KR19980703048A (ko) 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
CA2234166A1 (en) 1995-10-10 1997-04-17 Patric James Hahn N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
NZ334031A (en) 1996-08-28 2000-07-28 Lilly Co Eli Migraine treatment using substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2- aminocyclohepta[b]benzofurans
JP2001501946A (ja) 1996-10-08 2001-02-13 イーライ・リリー・アンド・カンパニー 新規セロトニン５―ｈｔ▲下１ｆ▼アゴニスト
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU4961499A (en) 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
EP1089993B1 (en) 1998-06-30 2003-10-22 Eli Lilly And Company 5-ht1f agonists
WO2000034266A1 (en) 1998-12-11 2000-06-15 Eli Lilly And Company Indole derivatives and their use as 5-ht1f agonists
US6777428B1 (en) * 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
CA2360164A1 (en) 1999-02-10 2000-08-17 Eli Lilly And Company 5-ht1f agonists
JP2002537398A (ja) 1999-02-26 2002-11-05 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
JP5265838B2 (ja) 2000-07-13 2013-08-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キラルな化合物ｉ
US6650463B2 (en) * 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
US20050080112A1 (en) * 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
EP1581498A2 (en) * 2002-11-22 2005-10-05 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
JP2006523692A (ja) * 2003-04-18 2006-10-19 イーライ リリー アンド カンパニー ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
EP1651595A2 (en) * 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
BRPI0516915A (pt) 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
KR20060067738A (ko) * 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
KR100976063B1 (ko) * 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
JP5727457B2 (ja) 2009-04-02 2015-06-03 コルーシッド ファーマシューティカルズ， インコーポレイテッド ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
UA124433C2 (uk) 2016-12-06 2021-09-15 Колюсід Фармасьютікалз, Інк. Піридиноїлпіперидин, його застосування для лікування мігрені та фармацевтична композиція на його основі
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida

Also Published As

Publication number Publication date
LT2413933T (lt) 2018-02-26
US20250228839A1 (en) 2025-07-17
HK1243923A1 (zh) 2018-07-27
NO2023002I1 (no) 2023-01-05
JP2016188241A (ja) 2016-11-04
SI2413933T2 (sl) 2021-09-30
HUE037261T2 (hu) 2018-08-28
CY2023001I2 (el) 2023-06-09
JP7110446B2 (ja) 2022-08-01
ES2655881T5 (es) 2021-11-25
PL2413933T5 (pl) 2021-10-18
CN102753171A (zh) 2012-10-24
JP5727457B2 (ja) 2015-06-03
JP2018087247A (ja) 2018-06-07
LUC00295I2 (enExample) 2025-09-22
LTC2413933I2 (enExample) 2025-03-10
US20210401822A1 (en) 2021-12-30
JP2025020117A (ja) 2025-02-12
US20100256187A1 (en) 2010-10-07
DK2413933T3 (da) 2018-01-29
IL215483A0 (en) 2011-12-29
HRP20171742T1 (hr) 2018-02-09
MX2011010359A (es) 2012-02-23
AU2010232497A1 (en) 2011-11-24
EP2413933B1 (en) 2017-11-01
NL301214I1 (enExample) 2023-01-25
CA2757019C (en) 2018-05-15
JP2012522805A (ja) 2012-09-27
CN107412230A (zh) 2017-12-01
SI2413933T1 (en) 2018-04-30
FR23C1002I1 (fr) 2023-03-10
CY2023001I1 (el) 2023-03-24
JP2021152008A (ja) 2021-09-30
JP7566996B2 (ja) 2024-10-15
AU2010232497B2 (en) 2016-05-19
ES2655881T3 (es) 2018-02-22
WO2010115125A2 (en) 2010-10-07
JP2022163049A (ja) 2022-10-25
NO2413933T3 (enExample) 2018-03-31
JP2023175694A (ja) 2023-12-12
EP2413933A4 (en) 2012-09-19
WO2010115125A3 (en) 2011-02-17
EP2413933B2 (en) 2021-06-09
JP6887462B2 (ja) 2021-06-16
CY1119785T1 (el) 2018-06-27
NZ596161A (en) 2013-11-29
KR101697801B1 (ko) 2017-01-18
DK2413933T4 (da) 2021-08-23
JP2015013903A (ja) 2015-01-22
PT2413933T (pt) 2017-12-12
KR20110136893A (ko) 2011-12-21
HUS2300004I1 (hu) 2023-02-28
HRP20171742T4 (hr) 2021-08-06
LTPA2023502I1 (enExample) 2023-01-25
CA2757019A1 (en) 2010-10-07
IL215483A (en) 2017-07-31
EP2413933A2 (en) 2012-02-08
NL301214I2 (nl) 2023-04-19
US12257246B2 (en) 2025-03-25
FIC20230001I1 (fi) 2023-01-10
PL2413933T3 (pl) 2018-04-30
JP2019189617A (ja) 2019-10-31
JP7335397B2 (ja) 2023-08-29

Similar Documents

Publication Publication Date Title
FR23C1002I1 (fr) 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse
PL2504005T3 (pl) Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
EP2119477A4 (en) COMPOSITION FOR THE TREATMENT OF XEROSTOMY OR DRY MOUTH
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
ATE541845T1 (de) 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
LT3251678T (lt) Benzoksaborolo dariniai, skirti bakterinių infekcijų gydymui
FR2928832B1 (fr) Orthese de poignet, destinee au traitement du syndrome du canal carpien
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
EP2812004A4 (en) COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
EP2276469A4 (en) ALPHA-ADRENERGE RECEPTOR AGONISTS FOR THE TREATMENT OF BANDAGE DISEASE DISEASE DISEASES
EP2884994A4 (en) COMPOSITION FOR THE TREATMENT OF HYPERLIPIDEMIA WITH AN OXYNTOMODULIN DERIVATIVE
HUE061548T2 (hu) Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
EP2273989A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS
MA46490A1 (fr) Dérivés de nucléosides 4&#39;- fluoro-2&#39; - méthyle substitués
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
ITMI20110598A1 (it) Procedimento e apparecchio di comando per l&#39;adattamento del rumore di marcia
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
EP2872155A4 (en) BIOMATERIALS FOR IMPROVED IMPLANT HOST INTEGRATION
MA45552A (fr) Compositions destinées au traitement de l&#39;amylose
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
WO2012080641A8 (fr) Agonistes des recepteurs s1p et leur utilisation dans le traitement des infections du vih